Cargando…

Efficacy of a combined tool for stage I non-small cell lung cancer against lymph node metastasis

In patients with clinical stage I non-small cell lung cancer (NSCLC), the prediction of occult lymph node metastasis (LNM) based on a combination of morphology using high-resolution computed tomography (HRCT) and metabolism using positron emission tomography (PET)-CT is unknown. The present study ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakada, Takeo, Yabe, Mitsuo, Ohtsuka, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404702/
https://www.ncbi.nlm.nih.gov/pubmed/36039061
http://dx.doi.org/10.3892/ol.2022.13452
_version_ 1784773696924155904
author Nakada, Takeo
Yabe, Mitsuo
Ohtsuka, Takashi
author_facet Nakada, Takeo
Yabe, Mitsuo
Ohtsuka, Takashi
author_sort Nakada, Takeo
collection PubMed
description In patients with clinical stage I non-small cell lung cancer (NSCLC), the prediction of occult lymph node metastasis (LNM) based on a combination of morphology using high-resolution computed tomography (HRCT) and metabolism using positron emission tomography (PET)-CT is unknown. The present study evaluated the use of predictive radiological tools, chest CT and PET-CT, for occult LNM in patients with clinical stage I NSCLC. The records of patients who underwent lobectomy between July 2014 and November 2021 were retrospectively reviewed. The differences in clinicopathological parameters, including CT and PET, between the LNM and non-LNM groups were assessed. Pure solid tumor was defined as a consolidation-to-tumor ratio of 1. The optimal cut-off value for predictive radiological tools for LNM was assessed according to the area under the receiver operating characteristic (ROC) curve. The present study included 288 patients, of whom 39 (13.5%) had LNM; of these 38 (97.4%) were pure solid type. Larger consolidation size (CS), higher maximal standardized uptake (SUVmax) value and histological type were statistically associated with LNM (all P<0.05). The optimal cutoff values of CS and SUVmax for predicting LNM were 19 mm and 5.5 respectively, as assessed using the area under the ROC curve. The combination of CS ≥19 mm and SUVmax ≥5.5 demonstrated a markedly higher odds ratio (9.184; 95% CI, 4.345-19.407) than each parameter individually. The minimum values of CS and SUVmax associated with LNM were 10 mm and 0.8 respectively. Pure solid formation and CS as morphology and SUVmax as metabolism were useful tools that complemented each other in predicting LNM. The combined method of evaluating SUVmax and CS may identify eligibility for LN dissection. However, considering the minimum values of CS and SUVmax in LNM, it cannot affirm the omission of LN dissection for cases that do not meet the combined criteria using HRCT and PET-CT.
format Online
Article
Text
id pubmed-9404702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-94047022022-08-28 Efficacy of a combined tool for stage I non-small cell lung cancer against lymph node metastasis Nakada, Takeo Yabe, Mitsuo Ohtsuka, Takashi Oncol Lett Articles In patients with clinical stage I non-small cell lung cancer (NSCLC), the prediction of occult lymph node metastasis (LNM) based on a combination of morphology using high-resolution computed tomography (HRCT) and metabolism using positron emission tomography (PET)-CT is unknown. The present study evaluated the use of predictive radiological tools, chest CT and PET-CT, for occult LNM in patients with clinical stage I NSCLC. The records of patients who underwent lobectomy between July 2014 and November 2021 were retrospectively reviewed. The differences in clinicopathological parameters, including CT and PET, between the LNM and non-LNM groups were assessed. Pure solid tumor was defined as a consolidation-to-tumor ratio of 1. The optimal cut-off value for predictive radiological tools for LNM was assessed according to the area under the receiver operating characteristic (ROC) curve. The present study included 288 patients, of whom 39 (13.5%) had LNM; of these 38 (97.4%) were pure solid type. Larger consolidation size (CS), higher maximal standardized uptake (SUVmax) value and histological type were statistically associated with LNM (all P<0.05). The optimal cutoff values of CS and SUVmax for predicting LNM were 19 mm and 5.5 respectively, as assessed using the area under the ROC curve. The combination of CS ≥19 mm and SUVmax ≥5.5 demonstrated a markedly higher odds ratio (9.184; 95% CI, 4.345-19.407) than each parameter individually. The minimum values of CS and SUVmax associated with LNM were 10 mm and 0.8 respectively. Pure solid formation and CS as morphology and SUVmax as metabolism were useful tools that complemented each other in predicting LNM. The combined method of evaluating SUVmax and CS may identify eligibility for LN dissection. However, considering the minimum values of CS and SUVmax in LNM, it cannot affirm the omission of LN dissection for cases that do not meet the combined criteria using HRCT and PET-CT. D.A. Spandidos 2022-08-09 /pmc/articles/PMC9404702/ /pubmed/36039061 http://dx.doi.org/10.3892/ol.2022.13452 Text en Copyright: © Nakada et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Nakada, Takeo
Yabe, Mitsuo
Ohtsuka, Takashi
Efficacy of a combined tool for stage I non-small cell lung cancer against lymph node metastasis
title Efficacy of a combined tool for stage I non-small cell lung cancer against lymph node metastasis
title_full Efficacy of a combined tool for stage I non-small cell lung cancer against lymph node metastasis
title_fullStr Efficacy of a combined tool for stage I non-small cell lung cancer against lymph node metastasis
title_full_unstemmed Efficacy of a combined tool for stage I non-small cell lung cancer against lymph node metastasis
title_short Efficacy of a combined tool for stage I non-small cell lung cancer against lymph node metastasis
title_sort efficacy of a combined tool for stage i non-small cell lung cancer against lymph node metastasis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404702/
https://www.ncbi.nlm.nih.gov/pubmed/36039061
http://dx.doi.org/10.3892/ol.2022.13452
work_keys_str_mv AT nakadatakeo efficacyofacombinedtoolforstageinonsmallcelllungcanceragainstlymphnodemetastasis
AT yabemitsuo efficacyofacombinedtoolforstageinonsmallcelllungcanceragainstlymphnodemetastasis
AT ohtsukatakashi efficacyofacombinedtoolforstageinonsmallcelllungcanceragainstlymphnodemetastasis